[Plasmapheresis in the combined therapy of progressive forms of glomerulonephritis].
29 patients aged 6-16 with glomerulonephritis lasting 4-5 years received multimodality treatment with plasmapheresis as a component. The majority of the patients suffered from primary glomerulonephritis in mesangio- or membrano-proliferative morphological variants. Previous long-term conventional therapy (prednisolone, cytostatics, anticoagulants and antiaggregation drugs) failed. The test course comprised 1-3 plasmapheresis sessions (centrifuge method on [symbol: see text] apparatus), cyclophosphamide or maintenance methyl-prednisolone pulse therapy, heparin and curantil. One-third of the patients achieved remission lasting from 5 months to 3 years, in the other one-third the improvement was as short as 2-4 weeks, and the last one-third appeared non-responders. Improvement of clinical indices occurred in parallel with trends to reduction in the levels of CIC, IgG, B-lymphocytes, T-helpers, inhibition of lymphocyte succinate dehydrogenase activity, better phagocytosis. No complications which may prohibit plasmapheresis use in glomerulonephritis were observed. Adjuvant plasmapheresis use in glomerulonephritis treatment needs further studies.
Moskaleva
E S
ES
Ignatova
M S
MS
Korneeva
V A
VA
Muromtsev
Iu V
IuV
Tsvetkova
E I
EI
Parubinovskaia
N M
NM
Kharina
E A
EA
Katysheva
O V
OV
Krivonos
A V
AV
D000293:Adolescent; D000917:Antibody Formation; D002648:Child; D002908:Chronic Disease; D003131:Combined Modality Therapy; D004359:Drug Therapy, Combination; D005069:Evaluation Studies as Topic; D005921:Glomerulonephritis / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007111:Immunity, Cellular; D010956:Plasmapheresis / Q000295:instrumentation; D012074:Remission Induction; D013997:Time Factors
Plazmaferez v kompleksnoĭ terapii progressiruiushchikh form glomerulonefrita.